The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1427148
This article is part of the Research Topic Exploring the New Biomarkers and Clinical Indicators for Diabetes: Insights from Real-World Studies View all 27 articles
From Past to Present: Tracing the Trends of Diabetes Drug Trials in Mainland China
Provisionally accepted
Zengqing Ma
1,2
Xin Zhao
1*
Yu Lin
3
Hong Zhang
1,2*
Lianping Wu
1*
Yang Tao
1,2*
Hongjun Shi
1,2*
Susu Li
1*- 1 Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
- 2 Clinical Trial Center, Nanjing Gaochun People’s Hospital, Nanjing, China
- 3 Department of Respiratory and Critical Care Medicine, Gaochun People's Hospital, Nanjing, China
Background: This study aimed to analyze the changing trend of diabetes drugs clinical trials in China during 2013-2023, and provided a reference for the research and development of diabetes drugs. Methods: Diabetes drug clinical trial data were obtained from the registration and information disclosure platform of the National Medical Products Administration (NMPA) between January 1, 2013, and December 31, 2023. Trends of clinical trials on diabetes drugs were systematically analyzed in terms of characteristics, trial design, time trends, drug type, and indications. Results: From 2013 to 2023, a total of 1,256 diabetes drugs clinical trials have been registered on the NMPA platform, of which 1056 were chemical drugs and 184 were biological products. The indications are mainly type 2 diabetes mellitus (n=1237, 98.49%). Among them, 838 clinical trials have been completed, 379 were proceeding, and 39 have been terminated or suspended. There were 42 international multi-center clinical trials, and the remaining 1034 clinical trials were domestic. Bioequivalence trials were 691, accounting for 55.02%, followed by 340 phase I clinical trials and 169 phase III clinical trials. The leading units were mostly distributed in eastern China. The proportion of clinical trial sponsorship from domestic pharmaceutical companies is higher than that from overseas companies. Conclusions: China has made significant advancements in diabetes drug research and development over the past decade. However, problems such as serious drug homogeneity, and insufficient innovation have become increasingly prominent. The government, clinical trial institutions, and pharmaceutical companies must collaborate to promote the high-quality development of drug clinical trials.
Keywords: diabetes, Drug clinical trials, Research and development, Trends, Mainland China
Received: 03 May 2024; Accepted: 20 Dec 2024.
Copyright: © 2024 Ma, Zhao, Lin, Zhang, Wu, Tao, Shi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xin Zhao, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Hong Zhang, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Lianping Wu, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Yang Tao, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Hongjun Shi, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Susu Li, Department of Pharmacy, Gaochun People's Hospital, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.